Annals of Oncology 19: 1992–1999, 2008
doi:10.1093/annonc/mdn525
Published online 22 July 2008
review
Primary extranodal lymphomas of stomach: clinical
presentation, diagnostic pitfalls and management
A. Psyrri1,2, S. Papageorgiou1* & T. Economopoulos1
1Second Department of Internal Medicine Propaedeutic, Athens University Medical School, University General Hospital ‘Attikon’, Haidari, Greece; 2Department of Internal
Medicine, Yale University School of Medicine, New Haven, USA
Received 25 January 2008; revised 17 June 2008; accepted 20 June 2008
Gastrointestinal lymphoma is the most common form of extranodal lymphoma, accounting for 30%–40% of
cases. The most commonly involved site is the stomach (60%–75% of cases), followed by the small bowel,
ileum, cecum, colon and rectum. The most common histological subtypes are diffuse large B-cell lymphoma
(DLBCL) and marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT). Helicobacter
pylori infection has been implicated in the pathogenesis of MALT gastric lymphoma, but its role in gastric diffuse
large B-cell non-Hodgkin’s lymphoma (NHL) is controversial. The therapeutic approach for patients with gastric
NHL has been revised over the last 10 years. Conservative treatment with anthracycline-based chemotherapy
alone or in combination with involved-field radiotherapy has replaced gastrectomy as standard therapy in cases
with DLBCL. Additionally, MALT lymphomas are mainly treated with antibiotics alone, which can induce lasting
remissions in those cases associated with H. pylori infection. Nevertheless, various therapeutic aspects for
primary gastric lymphomas are still controversial and several questions remain unanswered. Among others, the
role of rituximab, consolidation radiotherapy as well as H. pylori eradication in histological aggressive subtypes
warrants better clarification.
Key words: diffuse large B-cell lymphomas, extranodal lymphomas, Helicobacter pylori infection, mucosa-
associated lymphoid tissue, primary gastric lymphomas
introduction
The term primary extranodal non-Hodgkin’s lymphoma (PE-
NHL) refers to lymphomas which present with disease at any
organ or tissue other than lymph nodes or spleen; the
symptoms at initial presentation are caused mainly from
extranodal involvement and after routine staging procedures,
the extranodal involvement remains the clinically dominant
site of the disease. PE-NHL comprise �25%–40% of non-
Hodgkin’s lymphoma (NHL) and may occur at any organ
[1, 2].
Primary non-Hodgkin’s lymphoma of the gastrointestinal
tract is the most commonly involved extranodal site and
represents 10%–15% of all NHL cases and 30%–40% of all
extranodal sites [3]. The most commonly involved site is the
stomach (60%–75% of cases), followed by the small bowel,
ileum, cecum, colon and rectum [4, 5]. All histological
categories of nodal lymphomas may also arise in the
gastrointestinal (GI), but the main two histological subtypes
(>90% of cases) are mucosa-associated lymphoid tissue
(MALT) NHL and diffuse large B-cell (DLBC) NHL (Table 1).
Primary gastric non-Hodgkin’s lymphoma (PG-NHL) is
localized in the stomach, with or without perigastric and/or
abdominal lymph node involvement, and constitutes 20%–30%
of all PE-NHL. PG-NHL shows an incidence of 1 per 100 000
of the population in Western countries, but the incidence is
progressively increasing. Any histological subtype can arise in
the stomach, but the main two histological subtypes (>90% of
cases) are MALT NHL and DLBC NHL. Helicobacter pylori
infection has been implicated in the pathogenesis of MALT PG-
NHL [6, 7], but its role in gastric DLBC NHL is controversial
[8].
The present review summarizes the clinical presentation,
diagnostic work-up and management of patients with primary
gastric lymphomas.
diagnosis and staging
Clinical presentation of PG-NHL is not specific and varied,
with abdominal pain being the most common symptom
followed by dyspepsia, vomiting nausea and anorexia. Weight
loss is common, but it is mainly associated with the localization
of the disease. Gastric bleeding as presenting symptom occurs
in 20%–30% of patients, while gastric occlusion and
perforation are less common [4]. Bone marrow involvement,
elevated lactate dehydrogenase (LDH) and B symptoms are less
re
v
ie
w
*Correspondence to: Dr S. Papageorgiou, Second Department of Internal Medicine
Propaedeutic, Atttikon General Hospital, 1 Rimini street, 124 62 Haidari, Greece.
Tel: +30-210-58-31-663; Fax: +30-210-53-26-454;
E-mail: sotirispapageorgiou@hotmail.com
ª The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
common in gastric compared with nodal lymphomas.
Endoscopy usually reveals nonspecific gastritis or peptic ulcer
with mass lesions being unusual [9]. Occasionally, PG-NHL
can present as a multifocal stomach disease with numerous
clonally identical foci in macroscopically unaffected tissue [10].
Therefore, gastric mapping of unaffected mucosa is crucially
recommended in order to establish diagnosis. Gastric MALT
lymphoma is characterized by the presence of lymphoepithelial
lesions that are formed by invasion of single glands by
aggregates of neoplastic cells with centrocyte morphology [11],
in contrast to aggressive lymphoma where lymphoma-
infiltrating cells show a centroblastic morphology [12].
Staging work-up for PG-NHL include complete
hematological biochemical examinations (including LDH and
b2-microglobulin), computerized tomography (CT) of chest,
abdomen and pelvis and bone marrow aspiration and biopsy.
Upper GI endoscopy and multiple biopsies from stomach,
duodenum, gastroesophageal junction and from abnormal-
appearing lesions are required. An endoscopic ultrasound
should be carried out to determine the depth of invasion and
the presence of perigastric nodes. Examination of the pharynx
by an otorhinolaryngologist should be carried out to exclude
infiltration of Waldeyer ring that is occasionally associated with
PG-NHL [13, 14]. In addition to routine histology and
immunohistochemistry, cytogenetic studies should be carried
out. FISH for the detection of three specific MALT-related
translocations is recommended. The pertinent genotypic
evaluations should be carried out at the time of diagnosis to
guide treatment decisions. Histochemistry (Genta stain or
Warthin–Starry stain) and breath test should be carried out to
determine the presence of an active H. pylori infection. If
histology is negative, serology should be undertaken to identify
truly negative H. pylori gastric MALT NHL which is �10% of
the cases.
Positron emission tomography (PET) scan bears
a documented diagnostic value only for DLBCLs but is
controversial for MALT lymphomas, which are frequently
reported as PET negative due to their indolent behavior and
small tumor volume of disease [15, 16].
The Ann-Arbor classification system [17] is not easily applied
to GI tract lymphomas and although alternative staging systems
have been proposed, the problem of ‘staging’ a PG-NHL is
controversial even today. The use of different staging systems
combined with the variability in staging procedures hamper
meaningful comparisons of published series. However, factors
that have consistently been associated with poor prognosis in
these series are involvement of paraortic (versus local) lymph
nodes, serosal penetration and intestinal (versus gastric) origin.
An International Workshop in 1994, during the fifth
International Conference on Malignant Lymphoma, proposed
a modification to Blackledge’s system, known as ‘Lugano
staging’ which examines separately local spreading to
neighboring anatomic sites [18]. More recently, in 2003,
a modified tumor–node–metastasis classification system—the
Paris staging system—was proposed in order to describe more
efficiently (i) the depth of tumor infiltration, (ii) extent of
nodal involvement and (iii) extent of local tissue infiltration by
lymphoma [19] (Table 2).
PG MALT lymphomas
Isaacson and Wright [20] first observed in 1983 that primary
low-grade gastric B-cell lymphoma and immunoproliferative
small intestinal disease share histological characteristics more
similar to MALT than those of peripheral lymph nodes. Gastric
MALT lymphomas represent the vast majority of the three
different types of marginal zone B-cell lymphomas (MZBCLs)
according to the Revised European-American Lymphoma
(REAL) classification [21]. MALT lymphomas comprise 50% of
PG-NHL and are often multifocal. They occur predominantly
in individuals >50 years, with a peak in the seventh decade, but
cases have been reported in younger patients (third decade or
even earlier). In �90% of cases, a strong association between
chronic H. pylori infection and MALT gastric lymphoma has
been found [22]. It is accepted that gastric MALT lymphomas
arise from MALT acquired as a consequence of H. pylori
infection and the bacterial infection plays a crucial role in the
genesis and development of this tumor [23]. H. pylori can be
demonstrated in the gastric mucosa of most cases with gastric
MALT lymphomas [6]. In addition, epidemiological studies
have demonstrated the association between H. pylori infection
and development of gastric lymphoma [24, 25]. Nevertheless,
host immune responses play a less well-defined role in MALT
lymphoma formation as indicated by the fact that only
a minority of H. pylori-infected patients will eventually develop
lymphoma.
As with other MZBCL, the cells of PG MALT are typically
CD20 positive and express surface and, to a lesser extent,
cytoplasmic immunoglobulin (Ig) showing light chain
restriction. Most cases express IgM and a few IgA or IgG, but
IgD expression is rare. In �50% of cases, they aberrantly
express CD43. In addition, MALT lymphomas contain
moderately high concentrations of CD3+ and CD5+ T cells, but
in the majority of cases the lymphoma cells themselves are CD5
negative.
Three translocations, t(11;18)(q21;q21), t(1;14)(p22;q32)
and t(14;18)(q32;q21), are specifically associated with MALT
lymphomas and the genes involved have been characterized.
Although these three translocations involve different genes,
they all converge on the activation of the same nuclear factor
Table 1. Distribution of the main histological types (according to the
REAL classification) in the Greek and German study for gastrointestinal
non-Hodgkin’s lymphoma [4, 5]
Histological type Greek study
(128 patients)
frequency (%)
German study
(371 patients)
frequency (%)
Diffuse large B-cell lymphoma 45 59
With MALT component 9 14
Without MALT component 36 45
MALT lymphoma of the marginal zone 48 38
Follicular lymphoma 2 0.5
Mantle cell lymphoma 1 1
Peripheral T-cell lymphoma 4 1.5
REAL, Revised European-American Lymphoma; MALT, mucosa-associated
lymphoid tissue.
Annals of Oncology review
Volume 19 | No. 12 | December 2008 doi:10.1093/annonc/mdn525 | 1993
kB (NF-kB) oncogenic pathway [23]. Translocation t(11;18),
very common in gastric MALT lymphomas as well as MALT
lymphomas at other anatomic sites (30% of MALT
lymphomas) [26], results in a chimeric fusion between AP12
and MALT1 genes [27, 28]. This translocation is not seen in H.
pylori gastritis and its presence is associated with extension of
the disease outside the stomach (regional lymph nodes and/or
distal sites) [29]. The t(11;18)(q21;q21) translocation as well as
the t(1;14)(p22;q32) can identify cases that will not respond to
H. Pylori eradication [30].
In H. Pylori-associated gastritis and at the early stages of
MALT lymphoma, development antigens expressed by H.
pylori in conjunction with antigen-specific T cells activate the
antigen receptor of polyclonal B cells and lead to the
interaction of BCL10 and MALT1 proteins and consequently
the activation of NF-kB pathway. During the long course of
a chronic infection and persistent antigenic stimulation,
a subclone may acquire one of the MALT lymphoma-specific
translocations and develop a growth advantage. As a result,
constitutive activation of NF-kB pathway occurs
independently of H. pylori infection and the eradication of the
bacterium does not reverse the disease process [23]. The
scoring system proposed by Wotherspoon et al. [22] reflects
this spectrum of proliferation from polyclonal to monoclonal
state.
High-grade MALT lymphomas are equivalent to DLBCL in
the REAL classification [21] and they have probably
transformed from low-grade MALT lymphomas as they share
common clone-specific Ig heavy chain gene rearrangements
with low-grade lesions [31].
treatment of early stage gastric MALT
lymphomas
antibiotic therapy
More than 20 studies have shown a high rate of complete
remission (CR) of low-grade MALT lymphomas confined to
the stomach following eradication of H. pylori with antibiotics
[32–36]. Therefore, antibiotic treatment is a reasonable initial
treatment in low-grade gastric MALT lymphoma provided
thorough hematological and endoscopic follow-up takes place.
Thorough endoscopic follow-up is recommended because
initial diagnostic gastric biopsies do not exclude the coexistence
of aggressive lymphoma which requires cytotoxic
chemotherapy. Breath test 2 months after treatment to confirm
H. pylori eradication and repeat endoscopies with biopsies
every 6 months for 2 years and then annually to document
remission of the lymphoma are recommended. Despite the fact
that eradication of H. pylori may take place within 1 month of
completion of drug therapy, disappearance of lymphoma may
take several months and histologic CR may be delayed up to 18
months. When remission occurs, it appears to be stable. If
relapse occurs, it is usually associated with H. pylori reinfection.
Indications also exist that stage I patients with minimal
histological lymphoma residuals after H. pylori eradication
show a favorable course when treated only by regular follow-up
with endoscopies and multiple biopsies without administration
of oncological therapy, suggesting the potential role of watch
and wait strategy in these patients [37, 38]. In patients with
histological CR, lymphoma clone can be detected by PCR
analysis of the rearranged Ig gene on postremission gastric
Table 2. Comparison of ‘Lugano’ and ‘Paris’ staging system for primary GI lymphomas
Lougano staging system [18] TNM Paris system [19] Lymphoma extension
Stage I T1–3 N0 M0 Lymphoma confined to GI tract.
Single primary site or noncontiguous lesions.
Stage I1 T1m N0 M0 Confined to mucosa
Stage I2: infiltrating the
gastric wall up to the serosa
T1sm N0 M0 Lymphoma infiltrates the submucosa
T2 N0 M0 Lymphoma infiltrates muscularis propria or subserosa
T3 N0 M0 Lymphoma penetrates serosa
Stage II T1–3 N1–2 M0 Lymphoma extending to abdominal lymph nodes
Stage II1 T1–3 N1 M0 Involvement of local (paragastric) lymph nodes
Stage II2 T1–3 N2 M0 Involvement of distant (mesenteric, para-aortic,
paracaval, pelvic, inguinal) lymph nodes
Stage IIE T4 N0–2 M0 Infiltration of adjacent organs or tissues by direct infiltration
Stage IV: extranodal involvement
or concomitant supradiaphragmatic
nodal involvement
T1–4 N3 M0 Spread to extraabdominal lymph nodes
T1–4 N0–3 M1 Noncontinuous involvement of separate site in
GI tract (e.g. stomach and rectum)
T1–4 N0–3 M2 Noncontinuous involvement of other organs
(e.g. tonsils, parotid gland, ocular adnexa, liver and spleen)
or tissues (e.g. peritoneum and pleura)
T1–4 N0–3 M0–2 B0 Bone marrow not involved
T1–4 N0–3 M0–2 B1 Lymphomas infiltrates bone marrow
A Presence of systemic symptoms
(fever, night sweats and weight loss >10% BW)
B Absence of systemic symptoms
X Bulky mass (lesion of 10 cm or more in the longest diameter)
GI, gastrointestinal; TNM, tumor–node–metastasis; BM, body weight.
review Annals of Oncology
1994 | Psyrri et al. Volume 19 | No. 12 | December 2008
biopsies in 50% of the cases. This group should be observed
closely, whereas long-term negative PCR may indicate cure of
the disease [39].
therapy of cases refractory to antibiotics
or H. Pylori negative
There are no treatment guidelines for the management of
patients who show unresponsiveness to antibiotics or for the
subset of H. pylori-negative cases. This latter group of patients
usually does not respond to antibiotics. A choice can be made
between conventional therapeutic approaches.
Radiation therapy (RT) alone is a reasonable treatment
option in patients with early-stage (stages I and II) gastric
MALT lymphomas refractory to antibiotics. Two small
prospective series have shown a 100% complete response rate
following RT with a median dose of 30 Gy. The first study by
Yahalom [40] from Memorial Sloan-Kettering Cancer Center
demonstrated only one treatment failure at a median follow-up
of 18 months, whereas the one from Schechter et al. [41]
showed no treatment failure at a median follow-up of 27
months. Additionally, Tsang et al. [42] reported on 85 patients
with MALT lymphoma (17 patients with gastric MALT NHL)
receiving RT alone that up to 90% of patients attained a CR
with excellent 5-year progression free and overall survival (OS)
rates of 98% and 77%, respectively. With the recent evolvement
of CT radiotherapy planning, advanced techniques such as
three-dimensional conformal radiotherapy and intensity
modulated radiotherapy have facilitated the determination of
the clinical target volume, thereby reducing the toxicity that is
related to the irradiation of normal gastric mucosa and of
nearby organs (especially the left kidney). However, side-effects
of RT are encountered, most frequently anorexia, nausea and
vomiting. Although with the standard dose (30–35 Gy), no
delayed toxicity (such as peptic ulcers or GI haemorrhaging)
has been reported; the long-term effects of RT on the structure
and function of the gastric mucosa remain to be clarified.
There is no consensus regarding the role of adjuvant
chemotherapy after antibiotic treatment. The role of
chemotherapeutic agents such as alkylating agents, nucleoside
analogues or combination chemotherapy for gastric MALT
lymphomas refractory to antibiotics has been tested, but only
limited data especially on untreated patients with localized
disease exist to date. Recently, Nakamura et al. [43] reported
CR rates of 89% after oral monotherapy with
cyclophosphamide 100 mg/day on patients with gastric MALT
NHL, refractory to antibiotic therapy. In this study, the results
were comparable to the results achieved after RT; hence, oral
monotherapy with cyclophosphamide might also be a suitable
second-line therapeutic option after failure of H. pylori
eradication therapy. The role of the translocation t(11;18) for
the prediction of response to chemotherapy is yet under
investigation. Recent data support that for oral alkylating
agents such as chlorambucil or cyclophhosphamide, the
presence of this translocation in gastric MALT NHL is
predictive of resistance [44]. CR rates after 1 and 8 years were
42% and 8% for t(11;18)-positive and 89% for t(11;18)-
negative patients, respectively (P = 0.0003, 8 years). Hence, oral
alkylating agents might only be administered in patients
without the translocation t(11;18). Nucleoside analogue named
cladribine or 2-chlorodeoxyadenosine has been tested in
a phase II study in patients with gastric (n = 19) and no-gastric
MALT NHL at any stage [45]. Patients had to be chemotherapy
naive, not responding to H. pylori eradication therapy in case of
gastric NHL or suffering from relapse after RT. 2-
Chlorodeoxyadenosine was administered at a dose of 0.12 mg/
kg body weight by i.v. infusion over 2 h on days 1–5 and was
repeated every 4 weeks. All patients responded to treatment
after a median number of four cycles, and 84% achieved CR
including all patients with gastric NHL. Three patients with
gastric NHL have relapsed locally after 13, 18 and 22 months
and were salvaged with RT. Gr
本文档为【结外淋巴瘤】,请使用软件OFFICE或WPS软件打开。作品中的文字与图均可以修改和编辑,
图片更改请在作品中右键图片并更换,文字修改请直接点击文字进行修改,也可以新增和删除文档中的内容。
该文档来自用户分享,如有侵权行为请发邮件ishare@vip.sina.com联系网站客服,我们会及时删除。
[版权声明] 本站所有资料为用户分享产生,若发现您的权利被侵害,请联系客服邮件isharekefu@iask.cn,我们尽快处理。
本作品所展示的图片、画像、字体、音乐的版权可能需版权方额外授权,请谨慎使用。
网站提供的党政主题相关内容(国旗、国徽、党徽..)目的在于配合国家政策宣传,仅限个人学习分享使用,禁止用于任何广告和商用目的。